GLENMARK PHARMACEUTICALS (GLENMARK) financials

GLENMARK PHARMACEUTICALS (GLENMARK) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Market Cap: ₹64,432Cr.
Current Price: ₹2,283
Stock P/E: 44.1
ROE: 3.87%
ROCE: 6.51%
Book Value: ₹856
Dividend Yield: 0.22%
52W High / Low: ₹2,538/1,793

In Jun 2026, GLENMARK PHARMACEUTICALS (GLENMARK) reported sales ₹2,435 Cr and net profit ₹736 Cr.

Annual TTM: sales ₹8,480 Cr, net profit ₹205 Cr.

Shareholding: Promoters 46.65% (Jun 2026), FIIs 20.89% (Jun 2026), DIIs 18.60% (Jun 2026), Government 0.04% (Jun 2026), Public 13.81% (Jun 2026).

GLENMARK quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	2,636	2,251	2,010	2,395	1,539	2,360	2,147	2,435
Expenses	1,857	1,757	1,669	1,667	1,717	1,864	2,115	1,822
Operating Profit	779	494	341	728	-178	496	32	613
OPM %	30%	22%	17%	30%	-12%	21%	1.5%	25%
Other Income	83	129	-91	-254	-646	-68	-61	338
Interest	12	8	13	15	23	22	18	23
Depreciation	55	55	56	58	59	59	60	62
Profit before tax	795	559	181	401	-906	347	-107	866
Tax %	25%	26%	18%	18%	-18%	19%	-31%	15%
Net Profit	595	414	148	330	-739	282	-74	736
EPS in Rs	21.09	14.66	5.24	11.70	-26.19	10.00	-2.62	26.07
Raw PDF	—	—	—	—	—	—	—	—

GLENMARK profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	6,713	7,568	8,142	8,221	7,891	9,226	8,440	8,480
Expenses	5,407	5,676	6,453	6,748	6,649	6,982	7,361	7,518
Operating Profit	1,305	1,892	1,689	1,473	1,242	2,244	1,079	962
OPM %	19%	25%	21%	18%	16%	24%	13%	11%
Other Income	624	469	1,044	490	6,238	177	-1,030	-437
Interest	256	266	236	207	277	49	79	87
Depreciation	139	151	160	184	202	219	236	241
Profit before tax	1,535	1,944	2,337	1,572	7,001	2,154	-266	199
Tax %	12%	15%	15%	23%	26%	25%	-25%	—
Net Profit	1,355	1,649	1,998	1,209	5,167	1,610	-201	205
EPS in Rs	48.01	58.46	70.80	42.84	183.12	57.07	-7.12	7.26
Dividend Payout %	5%	4%	4%	6%	1%	4%	-70%	—

GLENMARK balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	28	28	28	28	28	28	28	28
Reserves	11,914	13,198	14,781	16,710	17,849	22,942	24,476	24,122
Borrowings	3,134	3,574	3,704	3,738	3,221	707	830	107
Other Liabilities	2,066	2,152	2,104	2,438	3,487	3,736	2,700	5,228
Total Liabilities	17,143	18,952	20,618	22,914	24,586	27,414	28,033	29,485
Fixed Assets	1,413	1,612	1,722	1,752	1,746	1,756	1,979	2,028
CWIP	286	200	131	109	172	198	155	159
Investments	3,269	4,714	6,990	8,559	10,334	12,965	15,195	15,202
Other Assets	12,174	12,426	11,774	12,494	12,334	12,496	10,705	12,096
Total Assets	17,143	18,952	20,618	22,914	24,586	27,414	28,033	29,485

GLENMARK cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	2,490	1,579	1,243	1,216	1,474	-495	589	543
Cash from Investing Activity	-2,256	-1,607	-1,235	-897	-432	3,197	-490	569
Cash from Financing Activity	-155	-139	-81	-305	-978	-2,666	-95	-952
Net Cash Flow	79	-168	-73	14	64	35	3	160
Free Cash Flow	2,867	1,575	1,112	1,053	1,601	-690	249	266
CFO/OP	218%	147%	83%	95%	128%	30%	52%	58%

GLENMARK shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	46.65%	46.65%	46.65%	46.64%	46.64%	46.65%	46.65%	46.65%
FIIs	23.05%	23.51%	23.15%	20.62%	20.73%	19.20%	20.35%	20.89%
DIIs	13.21%	13.85%	14.60%	17.64%	18.61%	20.09%	19.28%	18.60%
Government	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%
Public	17.06%	15.96%	15.56%	15.05%	13.97%	14.02%	13.70%	13.81%
No. of Shareholders	1,93,949	1,95,059	1,92,724	1,90,210	1,98,789	2,01,584	1,96,105	2,11,418

GLENMARK key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	121	100	120	120	111	115	101	143
Inventory Days	141	115	94	102	117	130	156	153
Days Payable	258	217	201	208	225	307	249	326
Cash Conversion Cycle	4	-3	14	14	3	-62	8	-30
Working Capital Days	151	106	115	42	29	12	55	92
ROCE %	13%	11%	12%	11%	11%	10%	10%	7%

GLENMARKUpdated 13 Oct 2026, 5:26

Glenmark Pharmaceuticals

GLENMARKUpdated 13 Oct 2026, 5:26

Market Cap

₹64,432Cr.

Current Price

₹2,283

High / Low

₹2,538/1,793

Stock P/E

44.1

ROE3.87%

ROCE6.51%

Book Value₹856

Face Value₹1.00

Dividend Yield0.22%

About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	2144	62	1659	18	49	392	31	272	9.63
Sep 2023	2233	58	1790	54	50	389	22	302	10.72
Dec 2023	1365	74	1549	234	51	-76	-73	-20	-0.72
Mar 2024	2148	83	1651	5933	52	6295	27	4614	163.5
Jun 2024	2330	15	1698	56	53	618	27	454	16.08
Sep 2024	2636	12	1857	83	55	795	25	595	21.09
Dec 2024	2251	8	1757	129	55	559	26	414	14.66
Mar 2025	2010	13	1669	-91	56	181	18	148	5.24
Jun 2025	2395	15	1667	-254	58	401	18	330	11.7
Sep 2025	1539	23	1717	-646	59	-906	-18	-739	-26.19
Dec 2025	2360	22	1864	-68	59	347	19	282	10
Mar 2026	2147	18	2115	-61	60	-107	-31	-74	-2.62
Jun 2026	2435	23	1822	338	62	866	15	736	26.07

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	5086	30	3618	-86	119	1232	18	1008	37.14
Mar 2016	6115	36	4349	116	100	1747	15	1484	52.6
Mar 2017	7989	153	5089	-89	105	2553	16	2141	75.86
Mar 2018	5520	191	4417	326	96	1143	11	1014	35.95
Mar 2019	6305	224	4977	954	106	1952	17	1622	57.49
Mar 2020	6713	256	5407	624	139	1535	12	1355	48.01
Mar 2021	7568	266	5676	469	151	1944	15	1649	58.46
Mar 2022	8142	236	6453	1044	160	2337	15	1998	70.8
Mar 2023	8221	207	6748	490	184	1572	23	1209	42.84
Mar 2024	7891	277	6649	6238	202	7001	26	5167	183.12
Mar 2025	9226	49	6982	177	219	2154	25	1610	57.07
Mar 2026	8440	79	7361	-1030	236	-266	-25	-201	-7.12
TTM	8480	87	7518	-437	241	199	—	205	7.26

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	46.65%
FIIs	20.89%
DIIs	18.6%
Government	0.04%
Public	13.81%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Sep 2023	46.65%	24.79%	10.31%	0.04%	18.21%
Dec 2023	46.65%	23.71%	10.92%	0.04%	18.7%
Mar 2024	46.65%	21.38%	13.36%	0.04%	18.58%
Jun 2024	46.65%	20.98%	13.93%	0.04%	18.42%
Sep 2024	46.65%	23.05%	13.21%	0.04%	17.06%
Dec 2024	46.65%	23.51%	13.85%	0.04%	15.96%
Mar 2025	46.65%	23.15%	14.6%	0.04%	15.56%
Jun 2025	46.64%	20.62%	17.64%	0.04%	15.05%
Sep 2025	46.64%	20.73%	18.61%	0.04%	13.97%
Dec 2025	46.65%	19.2%	20.09%	0.04%	14.02%
Mar 2026	46.65%	20.35%	19.28%	0.04%	13.7%
Jun 2026	46.65%	20.89%	18.6%	0.04%	13.81%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	27	4925	410	2289	7651	1231	294	1660	4466	7651
Mar 2016	28	7338	787	1960	10113	1438	276	1858	6541	10113
Mar 2017	28	9408	2777	1787	14001	1596	271	1867	10267	14001
Mar 2018	28	10363	2981	1892	15265	1699	420	3213	9933	15265
Mar 2019	28	11914	3134	2066	17143	1413	286	3269	12174	17143
Mar 2020	28	13198	3574	2152	18952	1612	200	4714	12426	18952
Mar 2021	28	14781	3704	2104	20618	1722	131	6990	11774	20618
Mar 2022	28	16710	3738	2438	22914	1752	109	8559	12494	22914
Mar 2023	28	17849	3221	3487	24586	1746	172	10334	12334	24586
Mar 2024	28	22942	707	3736	27414	1756	198	12965	12496	27414
Mar 2025	28	24476	830	2700	28033	1979	155	15195	10705	28033
Mar 2026	28	24122	107	5228	29485	2028	159	15202	12096	29485

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	145	-176	-32	-64
Mar 2016	355	-1545	1223	32
Mar 2017	878	-2580	1879	177
Mar 2018	1124	-1137	-62	-75
Mar 2019	2490	-2256	-155	79
Mar 2020	1579	-1607	-139	-168
Mar 2021	1243	-1235	-81	-73
Mar 2022	1216	-897	-305	14
Mar 2023	1474	-432	-978	64
Mar 2024	-495	3197	-2666	35
Mar 2025	589	-490	-95	3
Mar 2026	543	569	-952	160

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	175	182	177	253	121	100	120	120	111	115	101	143
Inventory Days	161	182	172	195	141	115	94	102	117	130	156	153
Days Payable	343	306	221	273	258	217	201	208	225	307	249	326
Cash Conversion Cycle	-6	59	129	175	4	-3	14	14	3	-62	8	-30
Working Capital Days	79	108	170	232	151	106	115	42	29	12	55	92
ROCE %	33%	26%	29%	10%	13%	11%	12%	11%	11%	10%	10%	7%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of GLENMARK PHARMACEUTICALS (GLENMARK)?

The reported market capitalisation for GLENMARK PHARMACEUTICALS (GLENMARK) is ₹64,432Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of GLENMARK?

The current price shown for GLENMARK PHARMACEUTICALS (GLENMARK) on Fincrux is ₹2,283 with a 52-week high/low of ₹2,538/1,793.

What is the P/E ratio of GLENMARK PHARMACEUTICALS (GLENMARK)?

The stock P/E for GLENMARK PHARMACEUTICALS (GLENMARK) is 44.1 on Fincrux, with ROE at 3.87% and ROCE at 6.51%.

What were GLENMARK latest quarterly results?

For Jun 2026, GLENMARK PHARMACEUTICALS (GLENMARK) reported sales ₹2,435 Cr and net profit ₹736 Cr (figures in ₹ crore unless noted).

What are GLENMARK annual sales and net profit?

For TTM, GLENMARK PHARMACEUTICALS (GLENMARK) shows sales of ₹8,480 Cr and net profit of ₹205 Cr on the Fincrux profit & loss statement.

Who owns GLENMARK PHARMACEUTICALS (GLENMARK)?

Latest shareholding for GLENMARK PHARMACEUTICALS (GLENMARK) on Fincrux: Promoters 46.65% (Jun 2026), FIIs 20.89% (Jun 2026), DIIs 18.60% (Jun 2026), Government 0.04% (Jun 2026), Public 13.81% (Jun 2026).

Where can I find GLENMARK PHARMACEUTICALS (GLENMARK) financials?

GLENMARK PHARMACEUTICALS (GLENMARK) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show GLENMARK balance sheet and cash flow?

Yes. The GLENMARK PHARMACEUTICALS (GLENMARK) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 5:26